Shield Therapeutics plc
Company Profile
Shield is a commercial stage pharmaceutical company focused on the commercialisation of Accrufer®/Feraccru® (ferric maltol), an innovative oral iron therapy for iron deficiency differentiated from other irons by its efficacy, broad label and well-tolerated formulation. The Group has launched Accrufer® in the US with an exclusive, multi-year collaboration agreement with Viatris, Inc. Feraccru® is commercialised in the UK and European Union by Norgine B.V., that also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group
Investor Access
Management will hold the company’s AGM on 20 June 2024 at 2pm BST
The Annual Report and Accounts and Notice of AGM are available to view on the Company's website: https://www.shieldtherapeutics.com/investors-and-media/results-reports-and-presentations/Thursday 20 June 2024 at 2pm BST
| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | May |
| Interim Results* | September |
| AGM* | June |
* Months based on previous announcements of this kind
